

REVIEW ARTICLE DOI: 10.53555/jptcp.v30i2.4862

# DICLOFENAC: AN UPDATE ON ITS MECHANISM OF ACTION AND SAFETY PROFILE

### Mishari Mohammed Dhafer Al-Otaibi<sup>1</sup>\*, Eid Ghazy Hamdan Alotaibi<sup>2</sup>, Bander Mohammad Ali Al.Masoud<sup>3</sup>, Adel Saeed Saleh Al-Wadaei<sup>4</sup>, Abdullah Qabl Khuwaytim Almutairi<sup>5</sup>, Mohammed Badr Mubarak Alotaibi<sup>6</sup>

<sup>1\*</sup>Pharmacy, malotaibi91@moh.gov.sa, King Khalid Hospital in Al Kharj
<sup>2</sup>Pharmacy, Egalotaibi@moh.gov.sa, The first health cluster in Riyadh
<sup>3</sup>pharmaceutical, Bmalmasoud@moh.gov.sa, Al hareeq general Hospital
<sup>4</sup>pharmacy technician, asalwadai@moh.gov.sa, Prince Salman bin Mohammed Hospital in Dalam
<sup>5</sup>Pharmacist Assistant, Abqalmutairi@moh.gov.sa, Hotat Bani Tamim General Hospital
<sup>6</sup>Pharmacy Technician, malotaibi193@moh.gov.sa, Shaqra general hospital

\***Corresponding Author**: Mishari Mohammed Dhafer Al-Otaibi \*Pharmacy, malotaibi91@moh.gov.sa, King Khalid Hospital in Al Kharj

#### Abstract:

Diclofenac is a widely used nonsteroidal anti-inflammatory drug (NSAID) known for its effectiveness in managing pain and inflammation. It functions by inhibiting the enzyme cyclooxygenase, thereby reducing the production of inflammatory mediators. This essay provides an update on the mechanism of action and safety profile of diclofenac, highlighting recent research findings. The method involved an extensive review of the literature on diclofenac, focusing on its mechanism of action and safety considerations. The results indicate that diclofenac exerts its anti-inflammatory effects primarily by inhibiting the production of prostaglandins, while also possessing other of action. The safety profile of diclofenac has been the subject of ongoing debate due its potential cardiovascular gastrointestinal risks. Overall, this essay aims to enhance understanding of diclofenac's pharmacology and safety considerations

Keywords: diclofenac, mechanism action, safety, NSAID, cyclooxygenase.

#### Introduction:

Diclofenac, a member of the NSAID class of drugs, is commonly used to manage pain and inflammation associated with various conditions such as, menstrual cramps, and acute injuries. Despite its widespread use, the mechanism of and safety profile of diclofenac have been topics of interest and investigation in the medical community. Understanding how diclofenac exerts its therapeutic effects and its potential risks is essential for optimizing its clinical use. This essay provides an update on the mechanism of action of diclofenac, focusing on recent research findings, and explores its safety profile in light of current evidence.

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) commonly used for pain relief and reducing inflammation. Here's an update on its mechanism of action and safety profile: Mechanism of Action:

Diclofenac works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins. Prostaglandins are inflammatory mediators that contribute to pain, inflammation, and fever. By inhibiting COX, diclofenac reduces the production of prostaglandins, leading to its anti-inflammatory and analgesic effects.

Diclofenac is a non-selective COX inhibitor, meaning it inhibits both COX-1 and COX-2 enzymes. COX-1 is involved in maintaining normal physiological functions, such as protecting the stomach lining and promoting platelet aggregation, while COX-2 is primarily associated with inflammation. The inhibition of COX-1 by diclofenac can lead to gastrointestinal side effects, while inhibition of COX-2 provides the anti-inflammatory effects.

### Safety Profile:

Like other NSAIDs, diclofenac carries certain risks and potential side effects. The safety profile of diclofenac includes the following considerations:

Gastrointestinal Effects: Diclofenac can increase the risk of gastrointestinal complications such as stomach ulcers, bleeding, and perforation. Individuals with a history of gastrointestinal disorders or those taking higher doses of diclofenac are at greater risk. The risk can be minimized by using the lowest effective dose for the shortest duration necessary and considering gastroprotective agents when appropriate.

Cardiovascular Risk: NSAIDs, including diclofenac, have been associated with an increased risk of cardiovascular events such as heart attack and stroke, particularly with long-term and high-dose use. The risk may be higher in individuals with pre-existing cardiovascular conditions or those at an increased risk of cardiovascular disease. It is important to use the lowest effective dose for the shortest duration in patients with cardiovascular risk factors.

Renal Effects: NSAIDs, including diclofenac, can cause fluid retention and reduce kidney function, particularly in individuals with pre-existing kidney disease or compromised renal function. Monitoring renal function and hydration status is important, especially in high-risk patients.

Hypersensitivity Reactions: Diclofenac can rarely cause allergic reactions, including skin rashes, itching, and anaphylaxis. Individuals with a known hypersensitivity to NSAIDs should avoid diclofenac.

Hepatotoxicity: Although rare, diclofenac has been associated with liver damage. It is essential to monitor liver function, especially in individuals with pre-existing liver conditions or those taking other medications that can affect liver function.

Other Side Effects: Common side effects of diclofenac include gastrointestinal discomfort, headache, dizziness, and elevated blood pressure. Rare but serious side effects may include blood disorders, severe skin reactions, and gastrointestinal perforation.

It's important to note that the safety profile of diclofenac may vary depending on factors such as dosage, duration of use, individual health conditions, and concomitant medications. Healthcare professionals should evaluate the potential risks and benefits of diclofenac for each patient and consider alternative treatment options when appropriate.

This information is not exhaustive, and it's crucial to consult a healthcare professional or refer to the prescribing information and product labeling for comprehensive information on diclofenac's mechanism of action, safety profile, and specific precautions.

#### Method:

To gather information on diclofenac's mechanism of action and safety profile, a thorough review of the literature was conducted. PubMed, Medline, and Embase were searched for relevant articles published in peer-reviewed journals. Key search terms included "diclofenac mechanism of action," "diclofenac pharmacology," "diclofenac safety profile," and "diclofenac cardiovascular risk." Studies that provided insights into diclofenac's mechanism of action and safety considerations were included in the analysis. Data from preclinical and clinical studies were synthesized to provide a comprehensive overview of diclofenac's pharmacological properties and potential risks.

## **Results:**

Diclofenac exerts its anti-inflammatory, analgesic, and antipyretic effects primarily by inhibiting the enzyme cyclooxygenase (COX). By inhibiting COX, diclofenac reduces the synthesis of prostaglandins, which are key mediators of inflammation and pain. In addition to COX inhibition, diclofenac has been shown to modulate other pathways involved in inflammation, such as the nuclear factor kappa B (NF- $\kappa$ B) pathway. These additional mechanisms contribute to the overall efficacy of diclofenac in managing inflammatory conditions. However, the specific molecular and cellular targets of diclofenac beyond COX inhibition warrant further investigation.

The safety profile of diclofenac has raised concerns, particularly regarding its cardiovascular and gastrointestinal risks. Recent studies have highlighted the association between diclofenac use and an increased risk of cardiovascular events, such as myocardial infarction and stroke. This risk is thought to be related to the inhibition of COX-2 by diclofenac, leading to a prothrombotic state. Gastrointestinal side effects, including ulcers and bleeding, are also common with diclofenac use, necessitating caution in patients with a history of gastrointestinal disorders. Overall, the balance between the therapeutic benefits and potential risks of diclofenac must be carefully considered in clinical practice.

## **Discussion:**

The mechanism of action of diclofenac in inhibiting COX and reducing prostaglandin synthesis is well established and underlies its therapeutic effects in managing pain and inflammation. However, the safety profile of diclofenac, particularly its cardiovascular and gastrointestinal risks, remains a topic of debate. While diclofenac is effective in relieving pain and inflammation, healthcare providers must weigh the benefits against the potential risks when prescribing this medication. Alternative treatment options with a lower risk of adverse effects should be considered for patients at higher risk of cardiovascular events or gastrointestinal complications. Future research should focus on elucidating the molecular targets of diclofenac beyond COX inhibition and developing strategies to minimize its adverse effects.

## **Conclusion:**

In conclusion, diclofenac is a valuable NSAID with established efficacy in managing pain and inflammation. Its mechanism of action involves the inhibition of COX and subsequent reduction in prostaglandin synthesis. Despite its effectiveness, diclofenac poses cardiovascular and gastrointestinal risks that require careful consideration in clinical practice. Healthcare providers should be aware of these potential risks and monitor patients closely when prescribing diclofenac. Continued research on diclofenac's pharmacology and safety profile is essential for optimizing its use and minimizing adverse effects.

## **References:**

- 1. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse JZ. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009; 143(3):238-45.
- 2. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894):769-79.
- 3. Shah SS, Ohlstein EH, Hauser KL, DeYoung M. Characterization of the in vivo cyclooxygenaseinhibitory properties of nonsteroidal anti-inflammatory drugs. Adv Prostaglandin Thromboxane Leukot Res. 1986; 16:37-44.
- 4. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008; 118(18):1894-909.

- 5. Brune K, Hinz B. The discovery and development of anti-inflammatory drugs. Pharmacol Ther. 2004; 102(2):131-61.
- 6. Rostom A, Dubé C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007; 146(5):376-89.
- 7. Rainsford KD. Fifty years of ibuprofen. Int J Clin Pract Suppl. 2013; 178:2-4.
- 8. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343(21):1520-8.
- 9. Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001; 15(5):801-20.
- 10. Goldstein JL, Chan FK, Lanza FL, et al. Haemoglobin decreases in NSAID users over time: a comparison between pre-selective and selective inhibitors. Aliment Pharmacol Ther. 2003; 18(5):485-9.